MedImmune LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1987-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://medimmune.com
Clinical Trials
292
Active:25
Completed:233
Trial Phases
5 Phases
Phase 1:147
Phase 2:81
Phase 3:25
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (270 trials with phase data)• Click on a phase to view related trials
Phase 1
147 (54.4%)Phase 2
81 (30.0%)Phase 3
25 (9.3%)Phase 4
15 (5.6%)Not Applicable
1 (0.4%)phase_2_3
1 (0.4%)A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination with Axitinib in Subjects with Advanced Renal Cell Carcinoma
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- AstraZeneca AB
- Target Recruit Count
- 93
- Registration Number
- 2023-509604-15-00
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇪🇸Institut Catala D'oncologia, L'hospitalet De Llobregat, Spain
🇪🇸Hospital Del Mar, Barcelona, Spain
IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.
Phase 1
Completed
- Conditions
- Advanced Solid Tumors
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 57
- Registration Number
- NCT04261075
- Locations
- 🇨🇭
Research Site, Lausanne, Switzerland
Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC
Phase 2
Withdrawn
- Conditions
- Microsatellite-stable Colorectal Cancer
- Interventions
- Drug: Standard of Care - mFOLFOX6Drug: E1 - mFOLFOX and durvalumabDrug: E2 - mFOLFOX6, durvalumab and oleclumabDrug: E3 - mFOLFOX6, durvalumab and monalizumab
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2020-09-21
- Lead Sponsor
- MedImmune LLC
- Registration Number
- NCT04145193
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 36
- Registration Number
- NCT04091373
- Locations
- 🇺🇸
Research Site, Daytona Beach, Florida, United States
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
Phase 1
Terminated
- Conditions
- Metastatic Microsatellite-stable Colorectal Cancer
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 61
- Registration Number
- NCT04068610
- Locations
- 🇪🇸
Research Site, Madrid, Spain
- Prev
- 1
- 2
- 3
- 4
- 5
- 54
- Next
News
No news found